John H. Stone
Massachusetts General Hospital · Johns Hopkins University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name John H. Stone as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04918147 · Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)National Institute of Allergy and Infectious Diseases (NIAID) · terminated · IgG4 Related Disease, IgG4-RD · study chair
- Ph3NCT04356937 · Efficacy of Tocilizumab on Patients With COVID-19Massachusetts General Hospital · completed · SARS-CoV 2
- Ph2NCT03669861 · Safety and Efficacy of Abatacept in IgG4-Related DiseaseMassachusetts General Hospital · completed · IgG4-related Disease
- Ph4NCT02169219 · Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated VasculitisMassachusetts General Hospital · completed · Granulomatosis With Polyangiitis, Microscopic Polyangiitis
- Ph1/Ph2NCT01584388 · Rituximab in IgG4-RD: A Phase 1-2 TrialMassachusetts General Hospital · completed · Retroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis
- Ph2/Ph3NCT00104299 · Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis · study chair
- Ph2/Ph3NCT00005007 · Etanercept for Wegener's GranulomatosisNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · completed · Wegener's Granulomatosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 14 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting T cell Subsets in Autoimmune DiseaseUM1AI144295 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2019 to 2026 · $333,918 awarded in 2026Same name and institution; not confirmed by an ID
- The First International Symposium on IgG4-Related Systemic DiseaseR13AR061254 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2011 · $22,500 awarded in 2011Same name and institution; not confirmed by an ID
- RAVEM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · fiscal years 2004 to 2006 · $34,586 awarded in 2006Same name and institution; not confirmed by an ID
- Translational Research in Systemic VasculitisK24AR049185 · NIAMS · JOHNS HOPKINS UNIVERSITY · fiscal years 2003 to 2006 · $25,302 awarded in 2006Same name and institution; not confirmed by an ID
- Vasculitis Outcome Measures: Development and ValidationU01AR051874 · NIAMS · JOHNS HOPKINS UNIVERSITY · fiscal years 2005 · $197,320 awarded in 2005Same name and institution; not confirmed by an ID
- RANDOMIZED CLINICAL TRIAL OF ETANERCEPT IN WEGENERS-264992240N01AR992240 · NIAMS · JOHNS HOPKINS UNIVERSITY · fiscal years 2004Same name and institution; not confirmed by an ID
- Vasculitis Outcome Measures: Development and ValidationR01AR051874 · NIAMS · JOHNS HOPKINS UNIVERSITY · fiscal years 2004 · $222,177 awarded in 2004Same name and institution; not confirmed by an ID
- GIANT CELL ARTERITIS AND BACTERIAL INFECTIONSR21HL065099 · NHLBI · JOHNS HOPKINS UNIVERSITY · fiscal years 1999 to 2000 · $163,900 awarded in 2000Same name and institution; not confirmed by an ID
- RANDOMIZED CLINICAL TRIAL OF ETANERCEPT IN WEGENER'SN01AR092240 · NIAMS · JOHNS HOPKINS UNIVERSITY · fiscal years 1999 to 2000 · $828,621 awarded in 2000Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- University of Michigan Clinical Autoimmunity Center of ExcellenceUM1AI144298 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Alan Fox, DINESH KHANNA · fiscal years 2019 to 2023Named on NCT04918147
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:48 UTC. The ranking covers the 200 most relevant of 51 PubMed records, and a shared surname and initials can bring in a namesake. All 51 on PubMed
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med · 20102,080 citationsRCR 63.1
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.N Engl J Med · 20201,046 citationsRCR 48.9
- Trial of Tocilizumab in Giant-Cell Arteritis.N Engl J Med · 2017987 citationsRCR 40.1
- Efficacy of remission-induction regimens for ANCA-associated vasculitis.N Engl J Med · 2013571 citationsRCR 20.0
- Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.Ann Intern Med · 2007399 citationsRCR 11.6
- A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.Arthritis Rheum · 2002395 citationsRCR 11.7
- Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.Medicine (Baltimore) · 2012376 citationsRCR 13.7
- Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum · 2005334 citationsRCR 9.4
- Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.Arthritis Rheum · 2003281 citationsRCR 8.9
- Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.Ann Intern Med · 2005224 citationsRCR 6.0